In ward level COVID-19 patients who received standard of care treatment (SOC) without tocilizumab (n = 6), AAT levels remained elevated (2·54 g/L ± 0·4 to 2·27 g/L ± 0·4 at day 28, NS, P = 0.1856) (supplemental Figure 3b). The gene discussed is SERPINA1; the disease is COVID-19.